SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Aeolus Pharmaceuticals (AOLS)

AOLS RSS Feed
Add AOLS Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Sheep
Search This Board: 
Last Post: 12/18/2017 4:50:13 PM - Followers: 18 - Board type: Free - Posts Today: 2

NASDAQ BB

http://www.aolsrx.com/

Strategy

Our strategy is to use non-dilutive capital wherever possible to develop our exciting platform of broad-spectrum catalytic antioxidant compounds in important unmet indications of national strategic importance.  We plan to continue to leverage that capital, like the investment made by U.S. government agencies, such as NIH-NIAID and NIH CounterACT, in AEOL 10150 as a medical countermeasure, to concurrently develop these promising compounds for use in significant unmet medical indications, like oncology. We are currently doing this with AEOL 10150, where we are leveraging the potential substantial government investment in research and development of AEOL 10150 as a medical countermeasure to develop the compound in oncology indications, where it would be used in combination with radiation therapy

Business Overview

 We are developing a platform of a new class of broad-spectrum catalytic antioxidant compounds based on technology discovered at Duke University and National Jewish Health. These compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme superoxide dismutase ("SOD").  While the benefits of antioxidants in reducing oxidative stress are well-known, research with our compounds indicates that metalloporphyrins can be used to affect signaling via ROS at the cellular level.  In addition, there is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation.

Our lead compound, AEOL 10150, is a metalloporphyrin specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.  We are leveraging the significant investment made by U.S. government agencies to develop this promising compound for use in oncology indications, where it would be used in combination with radiation therapy, and is currently in development for use as both a therapeutic and prophylactic drug. 

AEOL 10150 has previously been tested in two Phase I clinical trials with no serious adverse events reported.  Data have already been published showing that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.  Early next year we expect to release data showing the drug's impact, if any, when used in combination with radiation and/or chemotherapy.  In mid-2011 we expect to begin Phase I/II studies in non-small cell lung cancer ("NSCLC").

AEOL 10150 is also being developed as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome ("Pulmonary Acute Radiation Syndrome" or "Lung-ARS") as well as the gastrointestinal sub-syndrome of acute radiation syndrome ("GI-ARS"), both caused by exposure to high levels of radiation due to a radiological or nuclear event.  It is also being developed for use as a countermeasure for exposure to chemical vesicants such as chlorine gas and sulfur mustard gas.  AEOL 10150 has already performed well in animal efficacy and safety studies in each of these potential indications.  A significant portion of the funding for the medical countermeasure development programs to date has come from various government entities.    Although our management expects this funding to continue, there is no guarantee that it will do so.  We have submitted proposals to the Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as countermeasures for both Lung-ARS and cholorine gas exposure.  We are awaiting a final decision from BARDA on the contract.  If the contract from BARDA is awarded, it is expected that it will fund all of the costs to bring AEOL 10150 to FDA approval for that indication.

We have two programs underway for the development of our second drug candidate, AEOL 11207, for the treatment of epilepsy and Parkinson's disease.   These programs are being funded, in part, by private foundations and government grants.

 

 PDF Presentation Feb 2011:  www.aeoluspharma.com/wp-content/uploads/2010/10/Aeolus-Presentation-January-2011_Web.pdf

 

 

Share Structure:

60,470,718 outstanding shares as of  MAY 10,2011
200,000,000 shares authorized

~ 6 - 9 Million shares in the Float
as of Jan 26, 2011

 

 

Point of Contact:

CFO: Russell Skibsted

Public Company, Headquarters Location
26361 Crown Valley Pkwy., Ste. 150, Mission Viejo, CA 92691-7324, United States
(949)481-9825, (949)481-9829 fax

















AOLS (Daily)


AOLS (Weekly)








 

SureTrader
Interactive Brokers Advertisement
AOLS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AOLS News: Quarterly Report (10-q) 08/14/2017 05:09:19 PM
PostSubject
#608   heh, I like these tax-selling dips but I'll GetSeriousOK 12/18/17 04:50:13 PM
#607   Same here. AOLS has been around since jimbob4stocks 12/18/17 10:04:41 AM
#606   That "other company" is GSK. Aeolus, in their GetSeriousOK 12/16/17 10:19:28 AM
#605   Has the potential to explode! Will sit on tyfoidhana 12/15/17 04:55:24 PM
#604   I'm holding and waiting too. I agree this Sheep 12/15/17 02:21:51 PM
#603   This is one you tuck away. jimbob4stocks 12/15/17 01:12:00 PM
#602   From what turned to expectation of a banner Falco 12/15/17 05:33:00 AM
#601   Great time to average down jimbob4stocks 12/13/17 10:12:02 AM
#600   Couldn't agree more. Upside is too high jimbob4stocks 12/05/17 10:33:57 AM
#599   I'm thinking (OK, hoping) that BARDA will correct GetSeriousOK 12/04/17 07:11:06 PM
#598   Nice find! No 8k filed by Aeolus -- GetSeriousOK 12/04/17 07:02:15 PM
#597   Got my eye on it has potential and tyfoidhana 12/01/17 11:00:29 PM
#596   Ready for a update :) MADDSTACKER 12/01/17 01:56:37 PM
#595   Got my bid set in case someone feels tyfoidhana 12/01/17 06:51:20 AM
#594   http://www.barchart.com/snapopinion/stocks/AOLS mick 12/01/17 05:52:53 AM
#593   Been a long term investor in AOLS too Falco 11/30/17 04:54:16 AM
#592   Nearly six months since the FDA fast track Zlinger 11/28/17 11:02:11 PM
#591   Aeolus sold their 35% stake in Gencaro to jimbob4stocks 11/28/17 11:12:56 AM
#590   Someone got a nice buy this morning. Can't Sheep 11/27/17 03:52:21 PM
#589   Sun bitch talk about crumbs some one dropped tyfoidhana 11/22/17 10:13:36 AM
#588   Agreed tucked away .... for news day !! MADDSTACKER 11/22/17 09:43:53 AM
#587   Agreed someone needed cash..lol MADDSTACKER 11/22/17 09:43:23 AM
#586   Less than 9 mil mkt cap here...should be MERCURIAL 11/22/17 09:43:00 AM
#585   Dumb market seller. It was only 31K jimbob4stocks 11/22/17 09:42:32 AM
#584   Pos sellers MADDSTACKER 11/22/17 09:38:33 AM
#583   WTH...Come on $AOLS bring some news. MERCURIAL 11/22/17 09:37:54 AM
#582   Could be :) MADDSTACKER 11/21/17 06:41:38 PM
#581   I always thought paint downs were a MMs tyfoidhana 11/21/17 04:46:39 PM
#580   What pos keeps painting this down ? MADDSTACKER 11/21/17 03:55:40 PM
#579   Good point was going to raise my bid tyfoidhana 11/17/17 09:22:33 AM
#578   Don't drive up the price just yet. I'm Zlinger 11/17/17 01:07:43 AM
#577   LOL, I bought 20,000 shares yesterday and 20,000 GetSeriousOK 11/16/17 08:47:26 PM
#576   Can't wait to hear more about this wonder jimbob4stocks 11/16/17 03:06:52 PM
#575   I hope this continues. I expect we should Sheep 11/16/17 10:33:25 AM
#574   lmao. As Al Bundy would say.."toaster leavin's is MERCURIAL 11/16/17 09:53:03 AM
#573   sweet...let's goooo AOLS! MERCURIAL 11/16/17 09:52:00 AM
#572   You guys are trampling all over my crumbs tyfoidhana 11/16/17 09:50:48 AM
#571   10 k buy who's going drop 10 k MADDSTACKER 11/16/17 09:50:28 AM
#570   At least they are above .10. Not jimbob4stocks 11/16/17 09:49:49 AM
#569   Nice --------------Gap! tyfoidhana 11/16/17 09:48:53 AM
#568   Real smart let's stick a wall up ... MADDSTACKER 11/16/17 09:48:04 AM
#567   0.073 x 0.12 - very thin jimbob4stocks 11/16/17 09:43:25 AM
#566   I found it on msn headline news day tyfoidhana 11/16/17 07:13:04 AM
#565   Can you post a link to that article? Zlinger 11/15/17 09:38:05 PM
#564   Absolutely! This drug is a make or jimbob4stocks 11/15/17 03:42:52 PM
#563   Could see South Korea and Japan's government ordering MADDSTACKER 11/15/17 01:20:24 PM
#562   Could well be why there looking for the tyfoidhana 11/15/17 12:02:23 PM
#561   My L2 shows a gap between .075 and jimbob4stocks 11/15/17 11:00:55 AM
#560   Seems fitting! We're on the edge of jimbob4stocks 11/15/17 11:00:06 AM
#559   Show us the money!!!! $AOLS MERCURIAL 11/15/17 10:44:58 AM
PostSubject